



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

TAG Mail 19 July 2017

The purpose of TAGMail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAGMail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAGMail. NSW TAG may be contacted via email nswtag@stvincents.com.au or by calling 02 8382 2852.

TAG WEBSITE

****The following email discussions are available on the website:**

- Aprotinin use in NSW Hospitals
- Sodium oxybate for narcolepsy
- Management strategies for fentanyl injection shortage
- Risk mitigation strategies for hydromorphone storage

<http://www.ciap.health.nsw.gov.au/nswtag/pages/email-discussions.html>

****New LHD/Hospital resources for various High Risk Medicines available on website:**

- Hydromorphone
- Potassium

<http://www.ciap.health.nsw.gov.au/nswtag/pages/high-risk-medicines.html>

REPORTS AND PUBLICATIONS – AUSTRALIA

****AIHW**

- Potentially preventable hospitalisations in 2015-16

<http://www.myhealthycommunities.gov.au/our-reports/potentially-preventable-hospitalisations-update/july-2017>

****TGA**

- Codeine information hub (consumer factsheet, pharmacist factsheet and frequently asked questions regarding changes to patient access for medicines containing codeine)

<http://www.tga.gov.au/codeine-info-hub>

- Submissions received and TGA response: Reforms to the regulatory framework for complementary medicines

<http://www.tga.gov.au/submissions-received-and-tga-response-reforms-regulatory-framework-complementary-medicines>

- AusPAR added: Ephedrine hydrochloride (Ephedrine Hydrochloride MYX™) 25mg/1mL indicated in the treatment of hypotension secondary to spinal anaesthesia

<http://www.tga.gov.au/auspar/auspar-ephedrine-hydrochloride>

- AusPAR added: Golimumab (rmc) (Simponi™) extension of indications to include non-radiographic axial spondyloarthritis

<http://www.tga.gov.au/auspar/auspar-golimumab-rmc-1>

- AusPAR added: Etanercept (rch) (Brenzys™) indicated for rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis in adults (indications abbreviated)

<https://www.tga.gov.au/sites/default/files/auspar-etanercept-rch.pdf>

- AusPAR added: Certolizumab pegol (Cimzia™) extension of indications to include adult patients not previously treated with methotrexate or other DMARDs

<https://www.tga.gov.au/sites/default/files/auspar-certolizumab-pegol-170717.pdf>

- Metal-on-metal hip replacement implants

<http://www.tga.gov.au/metal-metal-hip-replacement-implants>

REPORTS AND PUBLICATIONS – INTERNATIONAL

**AHRQ Patient Safety Network

- Incidence and predictors of opioid prescription at discharge after traumatic injury.
<https://www.psnet.ahrq.gov/resources/resource/31084/incidence-and-predictors-of-opioid-prescription-at-discharge-after-traumatic-injury>
- Physician satisfaction with transition from CPOE to paper-based prescription.
<https://www.psnet.ahrq.gov/resources/resource/31186/physician-satisfaction-with-transition-from-cpoe-to-paper-based-prescription>

**FDA

- Neratinib (Nerlynx™) approved for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.
<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567309.htm>
- Sofosbuvir/ velpatasvir/voxilaprevir combination tablet (Vosevi™) approved to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis.
<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm>

**EMA

- EPAR added: Inotuzumab ozogamicin (Besponsa™) for the treatment of B-cell precursor acute lymphoblastic leukaemia (ALL).
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004119/human_med_002109.jsp&mid=WC0b01ac058001d124
- EPAR added: Dimethyl fumarate (Skilarence™) for the treatment of plaque psoriasis
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002157/human_med_002118.jsp&mid=WC0b01ac058001d124

**Gov.UK

- Drug misuse and dependence: UK guidelines on clinical management
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/628634/clinical_guidelines_2017.pdf

**The Joint Commission

- Discharge Instructions for Venous Thromboembolism (VTE): A Comprehensive Approach to Medication Management
https://www.jointcommission.org/discharge_instructions_for_venous_thromboembolism_vte/

**The National Academies of Sciences-Engineering-Medicine

- Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use
<http://nationalacademies.org/hmd/Reports/2017/pain-management-and-the-opioid-epidemic.aspx>

**NICE

- Constipation in children and young people: Diagnosis and management
<https://www.nice.org.uk/guidance/cg99>
- Ustekinumab for moderately to severely active Crohn's disease after previous treatment
<https://www.nice.org.uk/guidance/ta456>
- Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
<https://www.nice.org.uk/guidance/ta455>
- Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
<https://www.nice.org.uk/guidance/ta454>
- Bortezomib for treating multiple myeloma after second subsequent relapse (terminated appraisal)
<https://www.nice.org.uk/guidance/ta453>
- Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
<https://www.nice.org.uk/guidance/ta452>

****NIHR Signal**

- Insulin pumps not much better than multiple injections for intensive control of type 1 diabetes

<https://discover.dc.nihr.ac.uk/portal/article/4000703/insulin-pumps-not-much-better-than-multiple-injections-for-intensive-control-of-type-1-diabetes>

****Specialist Pharmacy Service**

- Comparative table of low molecular heparins

<https://www.sps.nhs.uk/articles/comparative-table-of-low-molecular-weight-heparins/>

****WHO**

- 1 in 10 infants worldwide did not receive any vaccinations in 2016 (News Release)

<http://www.who.int/mediacentre/news/releases/2017/infants-worldwide-vaccinations/en/>

MEDICATION SAFETY

****ISMP**

- QuarterWatch™ (2016 Annual Report) Part I: Consumers at risk from drug withdrawal symptoms

<http://www.ismp.org/newsletters/acute-care/showarticle.aspx?id=1171>

OTHER NEWS

****CEC**

- NOAC Information for Patients, Families and Carer documents had been translated into 6 languages (Arabic, Chinese Simplified, Chinese Traditional, Korean, Greek and Vietnamese). The documents can be accessed via the following link:

<http://www.cec.health.nsw.gov.au/patient-safety-programs/medication-safety/high-risk-medicines/information-for-patients>

****Sydney Morning Herald**

- Calls for medicine policy rethink as hospitals ration 'critical' painkiller fentanyl

<http://www.smh.com.au/national/calls-for-drug-policy-rethink-as-hospitals-ration-critical-painkiller-fentanyl-20170718-qxdv6.html>

PAPERS OF INTEREST

****Age and Ageing**

- Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis

<https://academic.oup.com/ageing/article-lookup/doi/10.1093/ageing/afx098>

- Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients: a multi-centre double-blind randomised controlled clinical trial

<https://academic.oup.com/ageing/article/doi/10.1093/ageing/afx124/3970846/Haloperidol-versus-placebo-for-delirium-prevention>

****AJHP**

- Effectiveness of interventions to improve medication use during rapid-sequence intubation in a pediatric emergency department

<http://www.ajhp.org/content/early/2017/07/10/ajhp160396>

****British Journal of Clinical Pharmacology**

- Quantitative efficacy of topical administration of tranexamic acid on postoperative bleeding in total knee arthroplasty

<http://onlinelibrary.wiley.com/doi/10.1111/bcp.13374/full>

- High-risk prescribing in an Irish primary care population: Trends and variation

<http://onlinelibrary.wiley.com/doi/10.1111/bcp.13373/full>

****BMJ**

- Risk of post-pregnancy hypertension in women with a history of hypertensive disorders of pregnancy: nationwide cohort study
<http://www.bmj.com/content/358/bmj.j3078>

****BMJ Quality and Safety**

- Reasons for computerised provider order entry (CPOE)-based inpatient medication ordering errors: an observational study of voided orders
<http://qualitysafety.bmj.com/content/early/2017/07/11/bmjqs-2017-006606>

****Cochrane Library**

- Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012638.pub2/full/>
- Oral paracetamol (acetaminophen) for cancer pain
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012637.pub2/full>

****European Heart Journal**

- Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary
<https://academic.oup.com/eurheartj/article/38/27/2137/2996308/Updated-European-Heart-Rhythm-Association>

****EJHP**

- Accuracy of best possible medication history documentation by pharmacists at an Australian tertiary referral metropolitan hospital
<http://ejhp.bmj.com/content/early/2017/07/11/ejhpharm-2016-001177>
- A telephone survey to determine the experiences of children and their parents/carers, following the initiation of a new medicine
<http://ejhp.bmj.com/content/early/2017/07/16/ejhpharm-2016-000925>

****JAMA**

- Association between Alendronate Use and Hip Fracture Risk in Older Patients Using Oral Prednisolone
<http://jamanetwork.com/journals/jama/article-abstract/2643309>

****JAMA Cardiology**

- Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial
<http://jamanetwork.com/journals/jamacardiology/fullarticle/2643429>

****JAMA Oncology**

- FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis
<http://jamanetwork.com/journals/jamaoncology/article-abstract/2628765>

****JAMA Psychiatry**

- Efficacy of Tramadol Extended-Release for Opioid Withdrawal - A Randomized Clinical Trial
<http://jamanetwork.com/journals/jamapsychiatry/fullarticle/2642924>

****MJA**

- Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations
<https://www.mja.com.au/journal/2017/207/2/antibiotics-acute-respiratory-infections-general-practice-comparison-prescribing>

****NEJM**

- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
<http://www.nejm.org/doi/full/10.1056/NEJMoa1707278>

****The Lancet**

- Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(17\)31444-7/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31444-7/fulltext)

****The Lancet - Infectious Diseases**

- Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis
[http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(17\)30359-6/fulltext](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30359-6/fulltext)

****Therapeutics and Clinical Risk Management**

- Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
https://www.dovepress.com/articles.php?article_id=33760

UPCOMING EVENTS (new additions in bold)

****HealthShare NSW and eHealth NSW Expo**

3rd August 2017, Rosehill Gardens, Rosehill
<http://www.hsnsw-ehnswexpo.health.nsw.gov.au/>

****Australian and New Zealand Intensive Care Society (ANZICS)**

Safety and Quality Conference: The Deteriorating Patient
7-8th August, Sofitel Sydney Wentworth
<http://www.sqao-anzics.com/>

****The University of Sydney – Sydney Ideas**

Data Science - the Future of Better Health?
15th August, The Westmead Institute for Medical Research, Westmead
<https://www.eventbrite.com.au/e/sydney-ideas-westmead-data-science-the-future-of-better-health-tickets-34093068285#tickets>

****ACI Mental Health Innovation Showcase**

17 August 2017, Kirribilli Club, 11 Harbourview Crescent, Lavender Bay NSW
<https://www.aci.health.nsw.gov.au/networks/mental-health/events/aci-mental-health-innovation-showcase>

****Clinical Excellence Commission**

Second NSW Antimicrobial Stewardship Forum
18th August 9am-4.30pm, Sydney CBD
<http://www.cec.health.nsw.gov.au/get-involved/events-and-webinars/upcoming-events/second-nsw-antimicrobial-stewardship-forum>

**** Healthcare Leaders Forum, Swissotel, Sydney, 22 & 23 August 2017**

<http://healthcareleaders.com.au/>

****CEC**

Mental Health and Falls Workshop
9am-4pm, 24th August, Barker St Randwick, NSW
<http://www.cec.health.nsw.gov.au/get-involved/events-and-webinars/upcoming-events/mental-health-and-falls-prevention-workshop>

****International Forum on Quality and Safety in Healthcare: Aim. Act. Achieve.**

24-26 August 2017, Kuala Lumpur
<http://internationalforum.bmj.com/kuala-lumpur/>

****6th World Congress of Clinical Safety 2017,**

6-8th September 2017, Roma, Italy
<http://www.iarmm.org/6WCCS/>

****ISQua's 34th International Conference**

'Learning at the System Level to Improve Healthcare Quality and Safety' 1- 4 October 2017, London

<http://www.isqua.org/Events/london-2017>

****CEC's 'Advanced Measurement and Variation Workshop'**

23rd October (additional workshop on 13th November)

<http://www.cec.health.nsw.gov.au/get-involved/events-and-webinars/upcoming-events/amv-workshop-oct2017>

****6th Annual NHMRC Symposium on Research Translation co-hosted with the Lowitja Institute**

Tuesday, 14 November 2017 to Wednesday, 15 November 2017, Brisbane, Australia

<https://icmsaust.eventsair.com/PresentationPortal/Account/Login?ReturnUrl=%2FPresentationPortal%2Fnhmrc-symposium-2017%2Fcall-for-abstracts>

****SHPA Medicines Management 2017 Conference**

16-19 November 2017

<http://mm2017shpa.com/>

****International Conference on Medical Cannabis and Cannabinoids**

'Policy, Science, and Medical Practice'

22-24 November, 2017, Prague CZ.

<http://medical-cannabis-conference.com/2017#.WRuzuEu7pFo>

****Cochrane Australia, Australasian Cochrane Symposium 'Towards living evidence',**

22-23rd November, Melbourne

<http://australia.cochrane.org/news/australasian-cochrane-symposium>

****APSA-ASCEPT Joint Scientific Meeting**

'Optimising medicines for optimal patient outcomes'

5-8 December, 2017, Brisbane Convention and Exhibition Centre

Abstract submissions now open

<http://www.asceptasm.com/2017-annual-scientific-meeting/program-workshops/>

You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at nswtag@stvincents.com.au if you have any questions regarding this.